



**NORRIS**  
**MEDICINES LIMITED**



Factory : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
Regd. Office : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
Telephone : (02646) 223462, 227530  
Fax : (02646) 250126  
E-mail : contact@norrispharma.com  
Website : www.norrispharma.com  
CIN : L24230GJ1990PLC086581

Date:14-02-2024

To  
The Manager  
Department of Corporate Services  
BSE Ltd.  
Dalal Street, Fort  
Mumbai - 400 001

**Sub. - : Reg. 33 - Unaudited financial results for the Quarter and nine months ended  
31<sup>st</sup>December 2023**

**Ref. - : Scrip Code - 524414**

Dear Sir / Madam,

The Board of Directors at their Meeting held on 14<sup>th</sup> February, 2024, has approved the Un-audited financial results for the Quarter and nine months ended 31<sup>st</sup>December 2023. As per Regulation 33 of Listing Regulations, the Financial Results and Limited Review Report are enclosed herewith for your records.

The Meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 03:30 P.M.

Kindly take the same on your records and acknowledge the receipt.

Thanking you,

Yours faithfully,

For Norris Medicines Limited

**Vimal D. Shah**  
Director  
DIN: 01506655



Encl: As above

**NORRIS MEDICINES LIMITED**

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrishpharma.com. Website: www.norrishpharma.com

CIN No.,L24230GJ1990PLC086581

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2023							
Rs. in Lakhs							
Sl. No.	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	(a) Revenue from Operations	64.63	255.52	316.42	414.80	714.51	835.82
	(b) Other Income	0.00	0.00	0.26	0.00	0.26	1.45
	<b>Total Income From Operations ( Net)</b>	<b>64.63</b>	<b>255.53</b>	<b>316.68</b>	<b>414.80</b>	<b>714.77</b>	<b>837.26</b>
2	Expenses						
	a. Cost of Materials Consumed	12.82	128.27	108.41	254.17	361.10	323.43
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	-7.40	73.87	54.78	-10.38	-3.48	12.85
	c. Employee Benefit Expenses	33.70	47.65	64.54	141.09	169.06	229.94
	d. Finance Costs	8.61	8.62	39.01	25.84	113.09	150.03
	e. Depreciation and Amortisation Expense	14.48	14.48	15.14	43.28	45.42	62.98
	f. Other expenditure	29.47	30.26	55.14	96.95	150.16	177.36
	<b>Total Expenses</b>	<b>91.69</b>	<b>303.14</b>	<b>337.02</b>	<b>550.95</b>	<b>835.34</b>	<b>956.59</b>
3	<b>Profit/ Loss before Tax (1-2)</b>	<b>-27.05</b>	<b>-47.62</b>	<b>-20.34</b>	<b>-136.15</b>	<b>-120.57</b>	<b>-119.33</b>
4	Tax Expense						
	a: Current Tax	0.00	0.00	0.00	0.00	0.00	-
	b: Deferred Tax	0.00	0.00	0.00	0.00	0.00	55.62
5	<b>Profit / Loss after Tax</b>	<b>-27.05</b>	<b>-47.62</b>	<b>-20.34</b>	<b>-136.15</b>	<b>-120.57</b>	<b>-174.95</b>
6	<b>Other Comprehensive Income</b>						
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	-
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	-
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	-
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	-
7	Total Comprehensive Income for the period	-27.05	-47.62	-20.34	-136.15	-120.57	-174.95
8	Paid-up equity share capital ( Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.27	-0.48	-0.20	-1.36	-1.21	-1.75

**Notes:**

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14/02/2024. The above results have been subjected to Limited Review by the Statutory Auditors of the Company.
- The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI ( Listing Obligation and Disclosure Requirements) Regulation,2015 and SEBI circular dated 05.07.2016.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- There are no exceptional/ extraordinary items during the quarter ended 31.12.2023
- Previous year/ period figures have been regrouped /rearranged wherever necessary to make them comparable with current period figures.

For Norris Medicines Limited

Vimal D Shah  
Director



Date: 14.02.2024  
Place: Ankleshwar



# BAHEDIA & ASSOCIATES

## CHARTERED ACCOUNTANTS



SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Towards Valia Road,  
GIDC Estate, ANKLESHWAR - 393 002. ☎ : (02646) 221708

*CA. B. L. Bahedia*

(B.Com., D.T.P., LL.B., FCA.)

Mobile No. : +91 98241 36264, 97252 20412

E-mail : bbahedia@yahoo.com/gmail.com

Web : www.bahediaassociates.icai.org.in

Ref. No. :

Date :

Review Report to Bombay Stock Exchange


We have reviewed the accompanying statement of unaudited financial results of **M/S NORRIS MEDICINES LIMITED**, REGD. OFF 801/P, GIDC ESTATE, ANKLESHWAR-393002, for the period ended 31<sup>st</sup> December, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

PLACE: - ANKLESHWAR

DATE: - 14-02-2024



For, BAHEDIA & ASSOCIATES  
CHARTERED ACCOUNTANTS  
(FRN: 114421W)

*B. L. Bahedia*

(CA: B.L.BAHEDIA)

PROPRIETOR

(ICAI Membership No. 048066)

UDIN:24048066BKADHO2424